AI Article Synopsis
- This study reports three cases of severe ovarian hyperstimulation syndrome (OHSS) in oncofertility patients who received a long-acting GnRH agonist after controlled ovarian hyperstimulation (COH) and embryo freezing.! -
- All three patients developed serious symptoms, including ascites and hyponatremia, indicative of severe early-onset OHSS despite using a GnRH agonist trigger to minimize risks.! -
- The findings suggest that using a long-acting GnRH agonist right after oocyte retrieval may heighten the risk of severe OHSS, prompting a recommendation to delay its initiation for high-risk patients.!
Article Abstract
Purpose: To report three cases of severe ovarian hyperstimulation syndrome (OHSS) among oncofertility patients receiving a long-acting GnRH agonist for ovarian suppression after controlled ovarian hyperstimulation (COH) with a GnRH antagonist protocol METHODS: Chart abstraction was completed for three patients at a single academic medical center. Patients included were undergoing fertility preservation prior to gonadotoxic chemotherapy. All patients underwent COH with GnRH antagonist protocol and embryo cryopreservation immediately followed by ovarian suppression with long-acting GnRH agonist. Main outcome measure was development of OHSS.
Results: Despite using GnRH agonist trigger and freezing all embryos, patients developed ascites, intermittent hyponatremia and hemoconcentration consistent with severe early-onset OHSS after receiving long-acting GnRH agonist immediately following oocyte retrieval for ovarian preservation.
Conclusions: Risk of severe OHSS may be increased when a long-acting GnRH agonist is used for ovarian suppression immediately following oocyte retrieval. A delay in initiating long-acting GnRH agonist after oocyte retrieval in patients at high risk for developing OHSS should be considered.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910346 | PMC |
| http://dx.doi.org/10.1007/s10815-020-02051-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of Endometriosis-Related Pain: Comparing the Effectiveness of Hormonal Therapy, Surgical Interventions, and Complementary Therapies.
Cureus
December 2024
Obstetrics and Gynecology, King Faisal University, Al Hasa, SAU.
Endometriosis is a chronic, inflammatory disease characterized by the presence of endometrial-like tissue outside the uterus, affecting women of reproductive age. It is linked with debilitating pain, infertility, and a notable impact on the patient's quality of life. This review aims to highlight the effectiveness of hormonal therapy, surgical procedures, and complementary therapies in managing endometriosis-related pain, providing a comprehensive overview of current treatment options and their implications for clinical practice.
View Article and Find Full Text PDFCardiovascular Risk in Prostate Cancer: State-of-the-Art Review.
JACC CardioOncol
December 2024
Division of Urology, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.
Cardiovascular disease is common in patients with prostate cancer and is a significant cause of death. Cardiovascular risk factors are frequent in this population and are often not addressed to thresholds recommended by cardiovascular practice guidelines. Androgen deprivation therapy reduces muscle strength and increases adiposity, increasing the risk for diabetes and hypertension, although its relationship with adverse cardiovascular events requires confirmation.
View Article and Find Full Text PDFIs There a Role for Hormonal Therapy in Men with Oligoasthenoteratozoospermia (OAT)?
J Clin Med
December 2024
Global Andrology Forum, Moreland Hills, OH 44022, USA.
Hormonal factors play an essential role as an underlying causative factor of oligoasthenoteratozoospermia (OAT), and these patients can benefit from hormonal medications that modulate the hypothalamic-pituitary-gonadal axis. This review aims to outline the various medications used as hormonal therapy in treating infertile men with OAT. This manuscript focuses on essential hormonal evaluation, identifying men who would benefit from treatment, selecting the appropriate medication, determining the duration of therapy, and evaluating hormonal treatment outcomes.
View Article and Find Full Text PDFHumanin alone and in Combination with GnRHa therapy attenuates ovarian dysfunction induced by prepubertal cyclophosphamide chemotherapy in female mice.
Reprod Toxicol
January 2025
Reproductive Genetics Department, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, China.
Prepubertal chemotherapy induced ovarian damage poses a significant threat to female fertility, particularly following cyclophosphamide (CP) treatment. Humanin (HNG), a small molecule polypeptide encoded by mitochondrial DNA, has a variety of effects, this study aimed to investigate the protective effects of HNG and its combination with conventional Gonadotropin Releasing Hormone Agonist (GnRHa) on ovarian function in a CP-induced damage model. The 21-day-old C57BL/6J female mice were randomly assigned to six groups: Control, CP model, HNG, HNG+CP, GnRHa+CP, and HNG+GnRHa+CP.
View Article and Find Full Text PDFIncomplete ovarian function suppression in premenopausal breast cancer patients treated with gonadotropin-releasing hormone agonists.
Cancer Treat Rev
January 2025
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 510120 Guangzhou, China; Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 510120 Guangzhou, China. Electronic address:
Background: Ovarian function suppression (OFS) has emerged as a crucial adjuvant therapy for premenopausal breast cancer patients. Some patients fail to achieve complete OFS with commonly used OFS drugs. The definition of incomplete OFS remains unclear, and large-scale data on its incidence are lacking.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!